Chronic Obstructive Pulmonary Disease Is Associated With Decreased Quality of Life in Bronchiectasis Patients: Findings From the KMBARC Registry.
COPD overlap
bronchiectasis
bronchiectasis health questionnaire
chronic obstructive pulmonary disease
quality of life
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
06
2021
accepted:
23
07
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
8
9
2021
Statut:
epublish
Résumé
Most studies have evaluated the impact of non-cystic fibrosis bronchiectasis (hereafter referred to as bronchiectasis) on quality of life (QoL) in patients with chronic obstructive pulmonary disease (COPD) using COPD cohorts. Accordingly, the impact of COPD on QoL in patients with bronchiectasis is not well-elucidated. We used the Korean Multicenter Bronchiectasis Audit and Research Collaboration (KMBARC) registry between August 2018 and December 2019, a prospective observational cohort that enrolled patients with bronchiectasis in Korea. We evaluated co-occurrence exposure to COPD in bronchiectasis patients, and the primary outcome was QoL according to the Bronchiectasis Health Questionnaire (BHQ). We also investigated factors associated with decreased QoL, defined as the lowest quartile of the total BHQ score. Of 598 patients with bronchiectasis, 372 (62.2%) had COPD. Bronchiectasis patients with COPD had a significantly lower total BHQ score compared with those without COPD [median = 63.1 (interquartile range: 54.8-68.6) vs. 64.8 (57.4-70.8),
Identifiants
pubmed: 34490307
doi: 10.3389/fmed.2021.722124
pmc: PMC8418120
doi:
Types de publication
Journal Article
Langues
eng
Pagination
722124Informations de copyright
Copyright © 2021 Kim, Kim, Jeong, Lee, Kim, Lee, Oh, Lee and Kim.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Respir Med. 2019 Aug;155:97-103
pubmed: 31326739
Lancet Glob Health. 2019 Sep;7(9):e1269-e1279
pubmed: 31402007
Int J Chron Obstruct Pulmon Dis. 2017 May 11;12:1401-1411
pubmed: 28546748
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1499-1507
pubmed: 32097051
Thorax. 2019 Jan;74(Suppl 1):1-69
pubmed: 30545985
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Ann Transl Med. 2020 Nov;8(21):1350
pubmed: 33313095
Ann Thorac Med. 2020 Jan-Mar;15(1):26-32
pubmed: 32002044
Sci Rep. 2015 Jun 16;5:10961
pubmed: 26077673
Int J Chron Obstruct Pulmon Dis. 2017 Nov 13;12:3301-3310
pubmed: 29180860
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596426
Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85
pubmed: 24328736
Respirology. 2021 Jun;26(6):619-621
pubmed: 33876470
Respir Med. 2018 Aug;141:47-51
pubmed: 30053971
COPD. 2014 Dec;11(6):605-14
pubmed: 24983298
BMC Pulm Med. 2020 Feb 18;20(1):45
pubmed: 32070324
Chest. 2017 May;151(5):982-992
pubmed: 27889361
Ann Transl Med. 2019 Dec;7(23):770
pubmed: 32042786
Chest. 1988 Mar;93(3):580-6
pubmed: 3342669
Int J Chron Obstruct Pulmon Dis. 2015 Jul 28;10:1465-75
pubmed: 26251586
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
Qual Life Res. 2013 Apr;22(3):597-605
pubmed: 22544417
Eur Respir J. 2019 Aug 29;54(2):
pubmed: 31048349
Eur Respir J. 2017 May 11;49(5):
pubmed: 28495688
Am J Respir Crit Care Med. 2004 Aug 15;170(4):400-7
pubmed: 15130905
Eur Respir J. 2014 May;43(5):1357-67
pubmed: 24232697
BMJ Open. 2020 Jan 19;10(1):e034090
pubmed: 31959610
Tuberc Respir Dis (Seoul). 2020 Jul;83(3):228-233
pubmed: 32578411
Eur Respir J. 2009 Aug;34(2):361-4
pubmed: 19648517
Respir Care. 2015 Nov;60(11):1585-91
pubmed: 26152471
Eur Respir J. 2018 Jan 31;51(2):
pubmed: 29386336
Clin Respir J. 2019 Aug;13(8):521-529
pubmed: 31295770
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941